Citius Oncology, Inc (CTOR) - Gross Margin

CTOR (Citius Oncology, Inc) - company brandmark

The integration of ESG standards and bioethics into drug development ensures the reliability of Citius Oncology, Inc. (CTOR). The gross profit margin clearly confirms the efficiency trend, where 28.90 determines the current status of the parameter. Physician confidence is growing due to targeted lymphoma treatment methods, although the lack of sales and dependence on external funding create a specific financial inertia for the business.

CTOR citiusonc.com Return on Gross Profit (08/14/2024 - 11/20/2026)

Analytical breakdowns and data insights for company Citius Oncology (CTOR)

- current quotes and average value forecast:
Fundamental valuation:CTOR, Citius Oncology Inc.
Signature product of citiusonc.com

To assess the fundamental stability of Citius Oncology, Inc. (CTOR), investors must analyze the efficiency of direct cost management. This gross profit margin measures the profit share after deducting the cost of goods sold, reflecting the recovery speed of operating margins amid turbulence. The high development cost of LYMPHIR and stringent FDA oversight make this indicator critical for confirming the commercial viability of the proprietary asset.

Main competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|HURA - Return on Gross Profit|protaratx.com - Gross Margin|FATE - Gross Margin|WHWK: Gross Margin|TScan Therapeutics (TCRX) - Gross Margin|Gross Profitability Champions Oncology|Gross Profitability XBIT|Gross Margin CVM|Return on Gross Profit OS Therapies Inc. OSTX|Gross Profitability Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Gross Profit Margin|ANL - Gross Profitability|Gross Profit Margin verupharma.com|TPST: Gross Margin|XLO - Return on Sales by Gross Profit|Gross Profitability Renovaro|Gross Margin muraloncology.com|Gross Margin KAPA|Return on Sales by Gross Profit OnKure Therapeutics, Inc.|Gross Margin GDTC (w2.cytomed.sg)|CRIS - Return on Gross Profit|Apollomics - Gross Margin|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit